BioSpace News Archive

Eisai Inc. and Merck announced results from presentations of new data and analyses of LENVIMA® (lenvatinib).

Jazz Pharmaceuticals plc announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy and a tolerable safety profile in the open-label Phase 3 TONES 5 study of excessive sleepiness (ES) in patients with narcolepsy or obstructive sleep apnea (OSA).

The Canadian Foundation for Healthcare Improvement (CFHI) and the Government of Newfoundland and Labrador today announced that 39 long term care organizations will participate in an 18-month province-wide program designed to improve dementia care through more appropriate use of antipsychotic medications.

Merck announced results from KEYNOTE-407, a pivotal, Phase 3 study evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC).

At the 66th ASMS Conference, Bruker announces innovative mass spectrometry products and workflows for breakthroughs in life-science research, in clinical research and large-cohort validations in phenomics and proteomics, in novel biopharma applications and in applied toxicology and forensics markets.

Five Prime Therapeutics, Inc. announced that a poster titled “FIGHT: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 (mFOLFOX6) in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer with a Dose Finding Phase 1 Lead-In” was presented today at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Genosco announced data from a Phase 1/2 study evaluating lazertinib (YH25448, GNS-1480) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Merck announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell carcinoma (RCC).

BerGenBio ASA announces that interim data from its Phase II clinical development programme with bemcentinib, a selective AXL inhibitor, was presented at a reception hosted yesterday by the company in Chicago, IL, USA.

Susan G. Komen® issued the following statement today regarding a new study partially funded by the organization – called Trial Assigning Individualized Options for Treatment, or TAILORx.